# OnCo record bmt-ctn-1102 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/bmt-ctn-1102/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "bmt-ctn-1102", "NCT02016781" ;
  schema:name "BMT CTN 1102"@en ;
  schema:alternateName "BMTCTN1102"@en, "CTN 1102"@en ;
  schema:description "BMT CTN 1102 settled whether older people with higher-risk myelodysplastic syndrome should be offered a stem-cell transplant: those who had a matched donor and went to transplant were far more likely to be alive three years later than those without a donor who had drug treatment instead, so transplant belongs in the plan for fit patients aged 50 to 75."@en ;
  schema:url <https://onco.cc/trials/bmt-ctn-1102/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02016781> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/mds-higher-risk/>, <https://onco.cc/cancers/mds/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:drugs <https://onco.cc/drugs/azacitidine/> ;
  onco:institutions <https://onco.cc/institutions/mcw-cancer-center/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-bmt-ctn-1102-transplant-older-mds-nakamura-jco-2021/> .